Document:

Exhibit
10.1

 

ASSET
PURCHASE AGREEMENT

 

This
Asset Purchase Agreement (the “Agreement”) is made this 1st day of May 2020, by and between PureBase
Corporation, a Nevada corporation (“Buyer”), and Quove Corporation, a Colorado corporation (“Seller”).

 

WHEREAS,
Seller desires to sell, and Buyer desires to purchase, on the terms and subject to the conditions in this Agreement, all of the
Seller’s assets used in connection with operating a gold processing plant known as Gold Bar Mill (the “Business”),
in exchange for the consideration set forth herein.

 

NOW,
THEREFORE, in consideration of the foregoing and of the respective promises, representations, warranties and covenants herein
contained, and other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, intending to
be legally bound, the parties agree as follows:

 

ARTICLE
I

SALE
AND PURCHASE OF ASSETS

 

Section
1.1 Purchased Assets. Upon the terms and subject to the conditions set forth herein, and on the basis of the
representations and warranties contained herein, at the Closing (as defined below), Seller shall sell, convey, transfer,
assign and deliver to the Buyer, and the Buyer shall purchase, acquire and accept from the Seller, all of the respective
right, title and interest in and to all the assets of the Seller, of every kind, nature and description, personal, tangible
and intangible, including without limiting the generality of the foregoing,

 

(i) all
equipment and those other physical assets necessary or reasonable to the operation of the Business, all as identified on Schedule
1.1(i);

 

(ii) all
licenses, franchises, grants, easements, exceptions, certificates, consents, permits, approvals, orders and other authorizations
of any court, tribunal, arbitrator, authority, agency, commission, official or other instrumentality of the United States, any
foreign country or any domestic or foreign state, county, city, local or other political subdivision (“Governmental Body”)
relating to the Assets, all of which have been identified on Schedule 1.1(ii) (collectively, the “Licenses”);

 

(iii) all
contracts, indentures, notes, bonds, leases, commitments, plans, arrangements, instruments or other agreements, in each case whether
written or oral (“Contracts”) relating to the Business of the Seller to which Seller is a party or to which
the business of the Seller is subject, including without limitation, warranties relating to the Assets, all of which have been
identified on Schedule 1.1(iii) (the “Assigned Contracts”)]; and

 

    	1

    	 

    

 

(iv) all
documents and records relating to the Assets (including without limitation, all records, technical design and know-how) and copies
of all accounting books, records, ledgers and electronic data processing materials (collectively, the “Records”).

 

The
assets, properties and rights to be conveyed, sold, transferred, assigned and delivered to Buyer pursuant to this Agreement are
sometimes hereinafter collectively referred to as the “Assets”.

 

Section
1.2 Assumed Liabilities. The Buyer shall not assume any liabilities greater than $10,000 (Ten Thousand Dollars) or
obligation arising out of a breach, violation or default by the Seller under any foreign, federal, state, local law, statute,
code, ordinance, rule or regulation (“Law”) or Contract (including any event occurring or fact or circumstance
existing as of or prior to the Closing Date (as defined below) that, with the passage of time or the giving of notice or both,
may become such a breach, violation or default).

 

Section
1.3 Purchase Price. As full and complete payment for the Assets, on the Closing Date the Buyer shall issue to Seller 6,200,000
(six million and two hundred thousand) shares of common stock of Buyer (the “Shares”). The Buyer shall have
the right by written instructions to Buyer to direct Buyer to issue all or a portion of the Shares directly to specified affiliates
or third-party assigns of Seller, provided however all Stock shall be subject to the representations, warranties and restrictions
set forth herein.

 

ARTICLE
II

CLOSING;
DOCUMENTS OF CONVEYANCE

 

Section
2.1 Closing. Subject to the satisfaction of the conditions set forth in Articles V and VI, the purchase and sale contemplated
hereby shall be consummated at a closing (referred to herein as the “Closing”) to be held at the offices of
The Crone Law Group, 500 Fifth Avenue, Suite 938, New York, NY 10110 within three business days after the satisfaction or, to
the extent permitted hereunder, waiver of all conditions set forth in Articles V and VI (other than those conditions that by their
nature are to be satisfied at the Closing, but subject to the satisfaction or, to the extent permitted, waiver of all such conditions)
(the “Closing Date”). The purchase and sale shall be deemed effective for all purposes as of the close of business
on the Closing Date.

 

    	2

    	 

    

 

Section
2.2 Actions to be Taken at the Closing. At the Closing, the (i) Buyer will issue the Shares to the Seller representing
full payment of the purchase price for the Assets, and (ii) Seller will take the following actions and deliver the following documents
to the Buyer:

 

	 	(a)	Seller
    will deliver the Assets, including without limitation, the Records.
	 	 	 
	 	(b)	Seller
    will execute and deliver a Bill of Sale and Assignment Agreement, substantially in the form attached hereto as Exhibit
    A (the “Bill of Sale”).
	 	 	 
	 	(c)	Seller
    will deliver all approvals, consents, ratifications, waivers or other authorization (“Consents”) of any
    Person (as defined below) and any requested resolutions and incumbency certificates of the directors and officers of the Seller
    required to enter into this Agreement and consummate the transactions described herein and referred to in Article V.

 

Section
2.3Power of Attorney. Effective upon the Closing Date, Seller hereby irrevocably constitutes and appoints the Buyer,
its successors and assigns, the true and lawful attorney of the Seller with full power of substitution, in the name of the Buyer,
or the name of the respective Seller, on behalf of and for the benefit of the Buyer, to collect all items being transferred, conveyed
and assigned to the Buyer as provided herein, to endorse, without recourse, checks, notes and other instruments in the name of
the Seller which have been transferred to the Buyer, to institute and prosecute, in the name of the Seller or otherwise, all proceedings
which the Buyer may deem proper in order to collect, assert or enforce any claim, right or title of any kind in or to the Assets,
to defend and compromise any and all actions, suits or proceedings in respect of any of the Assets, and to do all such acts and
things in relation thereto as the Buyer may deem reasonably advisable. The Seller agrees that the foregoing powers are coupled
with an interest and shall be irrevocable by the Seller directly or indirectly in any manner or for any reason.

 

Section
2.4 Purchase Price Allocation. The Shares, representing the purchase price for the Assets, shall be allocated among the
Assets according to an allocation that the parties undertake to settle upon, acting reasonably, and prior to Closing a copy of
which shall be attached hereto as Schedule 2.3. The Seller and the Buyer agree that in the absence of agreement, the amounts so
attributed to the Assets are the respective fair market values thereof, and shall file in mutually agreeable form all elections
required or desirable under the Internal Revenue Code of 1986, as amended in respect of the foregoing allocations.

 

ARTICLE
III

REPRESENTATIONS
AND WARRANTIES OF BUYER

 

The
Buyer represents and warrants to the Seller as follows on the date of this Agreement and as of the Closing Date:

 

Section
3.1 Organization, Qualification and Corporate Power. Buyer is a corporation duly organized, validly existing and in good
standing under the laws of the State of Nevada. Buyer is duly qualified to conduct business and is in good standing under the
laws of each jurisdiction in which the nature of its businesses or the ownership or leasing of its properties requires such qualification,
except where the failure to be so qualified or in good standing, individually or in the aggregate, has not had and would not reasonably
be expected to have a material adverse effect. Buyer has all requisite corporate power and authority to carry on the businesses
in which it is engaged and to own and use the properties owned and used by it.

 

    	3

    	 

    

 

Section
3.2 Authority; Binding Nature of Agreement. The Buyer has the absolute and unrestricted right, power and authority to enter
into and to perform its obligations under the Agreement; the execution, delivery and performance by Buyer of the Agreement has
been duly authorized by all necessary action on the part of Buyer. The Agreement constitutes the legal, valid and binding obligation
of Buyer, enforceable against it in accordance with its terms, subject to (i) laws of general application relating to bankruptcy,
insolvency and the relief of debtors, and (ii) rules of law governing specific performance, injunctive relief and other equitable
remedies. At the Closing, Buyer will deliver to Seller such evidence of the authorization of its execution, delivery, and performance
of the Agreement as Seller may reasonably request.

 

Section
3.3 Non-Contravention. Neither the execution, delivery or performance of the Agreement, nor the consummation of any of
the transactions contemplated by this Agreement, will directly or indirectly (with or without notice or lapse of time):

 

(a)
contravene, conflict with or result in a violation of (i) the provisions of the Articles of Incorporation or Bylaws of Buyer,
or (ii) any resolution adopted by the shareholders or Board of Directors of Buyer;

 

(b)
contravene, conflict with or result in a violation of, or give any Governmental Body or any individual, corporation (including
any non-profit corporation), general partnership, limited partnership, limited liability partnership, joint venture, estate, trust,
company (including any limited liability company or joint stock company), firm or other enterprise, association, organization
or entity (“Person”) the right to challenge any of the transactions contemplated by this Agreement or to exercise
any remedy or obtain any relief under, any federal, state, local, municipal, foreign or other law, statute, constitute, principle
of common law, resolution, ordinance, code, edict, decree, rule, regulation, ruling or requirement issued, enacted, adopted, promulgated,
implemented or otherwise put into effect by or under the authority of any Governmental Body (“Legal Requirement”)
or any order, writ, injunction, judgment, or decree to which Buyer or any of the assets owned or used by it, is subject; or

 

(c)
contravene, conflict with or result in a violation of, or breach of, or result in a default under, any provision of any Contract
to which Buyer is a party, or give any Person the right to (i) declare a default or exercise any remedy under any such Contract,
(ii) accelerate the maturity or performance of any such Contract, or (iii) cancel, terminate or modify any such Contract.

 

Buyer
is not and at the time of the Closing will not be required to make any filing with or give any notice to, or to obtain any Consent
from, any Person in connection with (i) the execution, delivery or performance of this Agreement or any of the other agreements
referred to in this Agreement, or (ii) the consummation of any of the transactions contemplated by this Agreement, other than
the filing of a Current Report on Form 8-K with the Securities and Exchange Commission (the “SEC”).

 

    	4

    	 

    

 

Section
3.4 The Shares. The Shares to be delivered by Buyer to Seller representing the complete purchase price for the Assets are
duly authorized, fully paid and non-assessable. None of the Shares were issued or will be transferred under this Agreement in
violation of any preemptive, preferential or similar rights of any Person. The delivery to Seller of the Shares pursuant to this
Agreement will vest in the Seller good and valid title to the Shares, free of any security interest, pledge, mortgage, lien, charge,
encumbrance, license, easement, right-of-way, cloud on title, adverse claim, preferential arrangement or restriction of any kind,
including, but not limited to, any restriction on the use, voting, transfer, receipt of income or other exercise of any attributes
of ownership (collectively, “Encumbrances”), other than as set forth in applicable federal and state securities
laws and regulations.

 

Section
3.5 Full Disclosure. This Agreement delivered by the Buyer to the Seller in connection with the transactions contemplated
herein, does not (i) contain any representation, warranty or information that is false or misleading with respect to any material
fact, or (ii) omit to state any material fact necessary in order to make the representations, warranties and information contained
and to be contained herein and therein not false or misleading.

 

ARTICLE
IV

REPRESENTATIONS
AND WARRANTIES OF SELLER

 

The
Seller represents and warrants to the Buyer as follows on the date of this Agreement and as of the Closing Date:

 

Section
4.1 Organization, Qualification and Corporate Power. Seller is a corporation duly organized, validly existing and in good
standing under the laws of the State of California. Seller is duly qualified to conduct business and is in good standing under
the laws of each jurisdiction in which the nature of its businesses or the ownership or leasing of its properties requires such
qualification. Seller has all requisite power and authority to carry on the businesses in which it is engaged and to own and use
the properties owned and used by it.

 

Section
4.2 Authority; Binding Nature of Agreement. Seller has the absolute and unrestricted right, power and authority to enter
into and to perform its obligations under this Agreement and the Bill of Sale (together, the “Transaction Documents”).
The Transaction Documents constitute the legal, valid and binding obligation of Seller, enforceable against Seller in accordance
with their respective terms. At the Closing, Seller will deliver to Buyer such evidence of the authorization of Seller’s
execution, delivery, and performance of the Transaction Documents as Buyer may reasonably request.

 

    	5

    	 

    

 

Section
4.3 Non-Contravention. Neither (i) the execution, delivery or performance of this Agreement or any of the other Transaction
Documents, nor (ii) the consummation of any of the transactions contemplated by this Agreement, will directly or indirectly (with
or without notice or lapse of time) (a) contravene, conflict with or result in a violation of (a) the provisions of the certificate
of incorporation and bylaws of Seller, or any resolution adopted by the directors and shareholders of Seller, (b) contravene,
conflict with or result in a violation of, or give any Governmental Body or other Person the right to challenge any of the transactions
contemplated by this Agreement or to exercise any remedy or obtain any relief under, any Legal Requirement or any order, writ,
injunction, judgment or decree to which Seller or the Assets is subject or (c) contravene, conflict with or result in a violation
of, or breach of, or result in a default under, any provision of any Contract to which Seller is a party, or give any Person the
right to (i) declare a default or exercise any remedy under any such Contract, (ii) accelerate the maturity or performance of
any such Contract or (iii) cancel, terminate or modify any such Contract. Attached are complete, true and accurate copies of the
current articles of incorporation and bylaws of the Seller, and all resolutions adopted by the Board of Directors and shareholders
of the Seller pertaining to this Agreement and the transactions contemplated hereby.

 

Seller
is not and will not be required to make any filing with or give any notice to, or obtain any Consent from, any Person in connection
with (i) the execution, delivery or performance of any of the Transaction Documents or any of the other agreements referred to
in this Agreement, or (ii) the consummation of any of the transactions contemplated by this Agreement, other than the Consent
from the Board of Directors and shareholders of the Seller (the “Seller’s Consents”).

 

Section
4.4 Undisclosed Liabilities. Seller has no liability (whether known or unknown, whether absolute or contingent, whether
liquidated or unliquidated and whether due or to become due) resulting or arising from, directly or indirectly, the Assets.

 

Section
4.5 The Assets. Seller has, and will have at the Closing, good, valid and marketable title to the Assets, free and clear
of any Encumbrances. Other than this Agreement, Seller has not sold, transferred, assigned or conveyed any of its right, title
and interest, or granted or entered into any option to purchase or acquire any of its right, title or interest, in and to the
Assets or any portion thereof. The Assets are in good operating condition and repair and are suitable for the use to which they
are put. The Assets constitute all of the properties and assets necessary to conduct the Business.

 

Section
4.6Contracts and Agreements. Schedule 4.9 sets forth all of the Contracts to which the Seller is a party or
by which it or any of the Assets are bound. 

 

    	6

    	 

    

 

Section
4.7Compliance with Laws; Permits. Seller has complied and is in compliance in all material respects with all
Laws applicable to it. No claims or investigations alleging any violation by the Seller of any Laws are pending or threatened.
Schedule 4.10 sets forth any claims or investigations resolved or otherwise concluded within the past five (5) years alleging
any violation of any Laws pertaining to the Seller or the Assets. Seller currently has all any approvals, authorizations, Consents,
licenses, permits or certificates of, or registrations with, a Governmental Body required or necessary for the ownership or operation
of the Assets or the conduct of the Business (collectively, “Permits”). All the Permits (i) are listed on Schedule
4.11; (ii) have been previously delivered to Buyer; and (iii) are in full force and effect. Seller has complied at all times,
and is presently in compliance, in all material respects, with the terms and conditions of all Permits. No loss, non-renewal,
suspension, modification or expiration of, nor any noncompliance with, any Permit is pending or threatened.

 

Section
4.8Environmental Matters. Seller has been, and has conducted the Business, in compliance with all Environmental Laws
and has not received any notice of any noncompliance with any Environmental Law or any liability or remedial or corrective obligation
thereunder or any Legal Proceeding relating thereto. No facts, events or circumstances with respect to the past or present operations
by the Seller or its affiliates would prevent continued compliance in all material respects with or give rise to any liability
(contingent or otherwise) under, any Environmental Law. There is no Release or Threat of Release of any Hazardous Materials at
or in the vicinity of the property where the Business was conducted or where the Assets are presently or ever where located. The
Seller has not received notice of an Environmental Condition and has never Released or at any time allowed or arranged for any
third party to Release, Hazardous Materials that, pursuant to the Comprehensive Environmental Response, Compensation and Liability
Act of 1980, as amended, or any similar state Law, has been placed on the National Priorities List or its state Law equivalent
or as to which the United States Environmental Protection Agency or any relevant state agency or other Governmental Body has notified
the Seller that it has proposed or is proposing to place on the National Priorities List or such state law equivalent.

 

“Environmental
Condition” means any condition with respect to the environment, whether or not yet discovered, which could or does result
in any liability to or against the Seller or the Buyer by any third party or Governmental Body.

 

“Environmental
Law” means any Law relating to the protection of human health, safety or the environment including: (A) all requirements
pertaining to reporting, licensing, permitting, controlling, investigating or remediating emissions, discharges, releases or threatened
releases of Hazardous Materials, whether solid, liquid or gaseous in nature, into the air, surface water, groundwater or land,
or relating to the manufacture, processing, distribution, use, treatment, storage, disposal, transport or handling of Hazardous
Materials, whether solid, liquid or gaseous in nature; and (B) all requirements pertaining to the protection of the health and
safety of employees or the public from exposure to Hazardous Materials.

 

    	7

    	 

    

 

“Hazardous
Material” means any substance, material or waste: (i) that is regulated, classified, or otherwise characterized under
or pursuant to any Environmental Law as “hazardous,” “toxic,” “pollutant,” “contaminant,”
or “radioactive,” including, without limitation, petroleum and its by-products, including asbestos, gasoline or diesel
fuel or other petroleum hydrocarbons or polychlorinated biphenyls (PCBs); (ii) the presence of which requires investigation or
remediation under any Environmental Laws; or (iii) that is toxic, explosive, corrosive, flammable, infectious, radioactive, carcinogenic
or mutagenic or otherwise hazardous and is regulated under Environmental Laws.

 

“Release”
means any releasing, spilling, leaking, pumping, pouring, emitting, emptying, discharging, injecting, escaping, leaching, disposing
or dumping into the environment.

 

Section
4.9 Insurance. All insurance policies pertaining to the Assets are listed on Schedule 4.13 and are in full force
and effect on the date hereof. The Seller has delivered to the Buyer true, correct and complete copies of such insurance policies.
Excluding insurance policies that have expired and been replaced in the ordinary course of business, no insurance policy has been
cancelled or not renewed within the last two (2) years and no threat has been made to cancel or not renew any insurance policy
of the Seller. The Seller has delivered to the Buyer: (i) a complete insurance claims history during the three (3) years ending
December 31, 2019 (including claims under former policies); and (ii) a list of all pending insurance claims (including such claims
made under any former policies). None of the insurers under any such insurance policies has rejected the defense or coverage of
any claim purported to be covered by such insurer or has reserved the right to reject the defense or coverage of any claim purported
to be covered by such insurer. 

 

Section
4.10Solvency. The Seller is not insolvent and will not be rendered insolvent by the sale and transfer of the Assets
as contemplated by this Agreement. As used in this section, “insolvent” means that the sum of the debts and other
probable liabilities of the Seller exceeds the present fair saleable value of the other assets of the Seller. Immediately after
giving effect to the Closing: (a) the Seller will be able to pay its debts as they become due in the usual course of business;
(b) the Seller will not have unreasonably small capital with which to conduct its proposed business; (c) the Seller will have
assets (calculated at fair market value) that exceed its liabilities; and (d) taking into account all pending and threatened litigation,
no final judgments against the Seller in actions for money damages are reasonably anticipated to be rendered at a time when, or
in amounts such that, the Seller will be unable to satisfy any such judgments promptly in accordance with their terms and all
other obligations of the Seller.

 

Section
4.11No OFAC Investigations. Neither the Seller nor any of its directors, officers, employees or agents is a Person
who: (a) is currently the subject of any investigation by the Office of Foreign Assets Control, Department of Treasury (“OFAC”)
or any other Governmental Body pursuant to any Laws administered by OFAC or any other Governmental Body (“Sanctions
Investigation”); or (b) is directly or indirectly owned or controlled by any Person who
is currently the subject of any Sanctions Investigation.

 

    	8

    	 

    

 

Section
4.12 Disclosure. Neither this Agreement nor any of the Schedules or Exhibits hereto, contains any untrue statement of a
material fact or omits a material fact necessary to make the statements contained herein or therein, in light of the circumstances
in which they were made, not misleading. No investigation or due diligence conducted by, or knowledge obtained by, the Buyer shall
limit, modify or negate any of the foregoing representations and warranties.

 

Section
4.13Securities Law Matters.

 

	 	(a)	Seller
    understands that the Shares are being offered and made in reliance on one or more exemptions from the registration requirements
    of United States federal and state securities laws and that the Buyer is relying upon the truth and accuracy of the representations,
    warranties, agreements, acknowledgments and understandings of the Seller set forth herein in order to determine the applicability
    of such exemptions and the suitability of Seller to acquire the Shares.
	 	 	 
	 	(b)	At
    no time was the Seller presented with or solicited by any leaflet, newspaper or magazine article, radio or television advertisement,
    or any other form of general advertising or solicited or invited to attend a promotional meeting otherwise than in connection
    and concurrently with such communicated offer.
	 	 	 
	 	(c)	Seller
    is acquiring the Shares for its own account and not with a view to their distribution within the meaning of Section 2(11)
    of the Securities Act. Seller is acquiring the restricted Shares for its own account as principal, not as a nominee or agent,
    for investment purposes only, and not with a view to, or for, resale, distribution or fractionalization thereof in whole or
    in part, and no other Person has a direct or indirect beneficial interest in the restricted Shares the Seller is acquiring
    herein. Further, the Seller does not have any Contract, undertaking or arrangement with any Person to sell, transfer or grant
    participations to such person or to any third person, with respect to the restricted Shares the Seller is acquiring.
	 	 	 
	 	(d)	Seller
    understands that the Buyer is under no obligation to register the restricted Shares under the Securities Act, or to assist
    the Seller in complying with the Securities Act or the securities laws of any state of the United States or of any foreign
    jurisdiction.

 

    	9

    	 

    

 

	 	(e)	Seller
    is an “accredited investor” (as that term is defined in Rule 501 of the General Rules and Regulations under the
    Securities Act by reason of Rule 501(a)(3)), and is (i) experienced in making investments of the kind represented by the Shares,
    (ii) able, by reason of the business and financial experience of its officers (if an entity) and professional advisors (who
    are not affiliated with or compensated in any way by the Buyer or any of its affiliates), to protect its own interests in
    connection with the acquisition of the Shares and (iii) able to afford the entire loss of its investment in the Shares. Seller
    has been provided an opportunity for a reasonable period of time prior to the date hereof to obtain additional information
    concerning the Buyer and the Shares.
	 	 	 
	 	(f)	 Seller
    understands that an investment in the Shares is a speculative investment which involves a high degree of risk and the potential
    loss of its entire investment. 
	 	 	 
	 	(g)	 Seller
    has received all documents, records, books and other information pertaining to its investment that has been requested by the
    Seller with respect to the Buyer and its business, including without limitation, its financial condition and control persons.
	 	 	 
	 	(h)	 The
    Shares are “restricted” (as that term is defined in Rule 144 promulgated under the Securities Act), and the certificate
    representing the Shares shall be endorsed with one or more of the following restrictive legends, in addition to any other
    legend required to be placed thereon by applicable federal or state securities laws: 

 

“THESE
SECURITIES HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED. THEY MAY NOT BE SOLD, OFFERED FOR SALE, PLEDGED
OR HYPOTHECATED IN THE ABSENCE OF A REGISTRATION STATEMENT IN EFFECT WITH RESPECT TO THE SECURITIES UNDER SUCH ACT OR AN OPINION
OF COUNSEL SATISFACTORY TO THE COMPANY THAT SUCH REGISTRATION IS NOT REQUIRED OR UNLESS TRANSFERRED PURSUANT TO ANY VALID EXEMPTION
FROM REGISTRATION AVAILABLE UNDER SUCH ACT.”

 

Section
4.14 Full Disclosure. The Transaction Documents delivered by Seller to Buyer in connection with the transactions contemplated
herein, do not (i) contain any representation, warranty or information that is false or misleading with respect to any material
fact, or (ii) omit to state any material fact necessary in order to make the representations, warranties and information contained
and to be contained herein and therein not false or misleading.

 

    	10

    	 

    

 

ARTICLE
V

CONDITIONS
PRECEDENT TO OBLIGATIONS OF BUYER

 

The
obligations of Buyer to consummate the transactions contemplated by this Agreement are subject to the satisfaction, at or prior
to the Closing, of each of the following conditions:

 

Section
5.1 Accuracy of Representations. Each of the representations and warranties made by Seller in this Agreement and in each
of the other Transaction Documents delivered to Buyer in connection with the transactions contemplated by this Agreement shall
have been accurate in all respects on the date of execution of this Agreement and on the Closing Date.

 

Section
5.2 Performance of Covenants. Each covenant or obligation that Seller is required to comply with or to perform at or prior
to the Closing shall have been complied with and performed in all respects.

 

Section
5.3 Consents. All necessary Consents required to be obtained in connection with the transactions contemplated by this Agreement,
including, but not limited to the Seller’s Consents, shall have been obtained (and copies thereof shall have been provided
to Buyer) and shall be in full force and effect.

 

Section
5.4 Agreements and Documents. Buyer shall have received a certificate executed by Seller containing the representation
and warranty of Seller that each of the representations and warranties set forth in Article IV is accurate in all respects as
of the Closing Date and that the conditions set forth in Article V have been duly satisfied.

 

Section
5.5 Officers Certificate. Buyer shall have received (i) a copy of Seller’s Articles of Incorporation, (ii) a copy
of the Bylaws of Seller, and (iii) a copy of the resolutions of the Board of Directors and shareholders of the Seller, authorizing
the execution of this Agreement and the consummation of the transactions contemplated hereby, each certified by an officer of
Seller.

 

Section
5.6 No Legal Proceedings. No Legal Proceeding shall be pending wherein an unfavorable judgment, order, decree, stipulation
or injunction would (i) prevent consummation of any of the transactions contemplated by this Agreement, or (ii) cause any of the
transactions contemplated by this Agreement to be rescinded following consummation, and no such judgment, order, decree, stipulation
or injunction shall be in effect.

 

ARTICLE
VI

CONDITIONS
PRECEDENT TO OBLIGATIONS OF SELLER

 

The
obligations of Seller to consummate the transactions contemplated by this Agreement are subject to the satisfaction, at or prior
to the Closing, of the following conditions:

 

Section
6.1 Accuracy of Representations. Each of the representations and warranties made by Buyer in this Agreement and in each
of the other Transaction Documents delivered to Seller in connection with the transactions contemplated by this Agreement shall
have been accurate in all material respects as of the Closing Date.

 

    	11

    	 

    

 

Section
6.2 Performance of Covenants. All of the covenants and obligations that Buyer are required to comply with or to perform
at or prior to the Closing shall have been complied with and performed in all material respects.

 

Section
6.3 Consents, Waivers, Releases. All Consents required to be obtained by the Buyer in connection with the transactions
contemplated by this Agreement shall have been obtained and shall be in full force and effect.

 

Section
6.4 Agreements and Documents. Seller shall have received a certificate executed by Buyer and containing the representation
and warranty that each of the representations and warranties set forth in Articles III are accurate in all material respects as
of the Closing Date and that the conditions set forth in Article VI have been duly satisfied.

 

Section
6.5 Officers Certificate. Seller shall have received (i) a certified copy of Buyer's Articles of Incorporation and all
amendments thereto, (ii) a copy of Buyer’ Bylaws, and (iii) a copy of the resolutions of the Board of Directors of Buyer,
authorizing the execution of this Agreement and the consummation of the transactions contemplated hereby, each certified by an
officer of each of the Buyer.

 

ARTICLE
VII

SURVIVAL
OF REPRESENTATIONS

AND
WARRANTIES; INDEMNIFICATION

 

Section
7.1 Survival. The right to bring claims or assert causes of action for breach of any covenants, agreements, representations
and warranties of the parties contained in this Agreement or in any certificate or other writing delivered pursuant hereto or
in connection herewith shall survive for a period of two years following the Closing Date, provided, however, that (i) the covenants
and agreements which by their terms do not contemplate performance after the Closing shall terminate as of the Closing; and (ii)
the covenants and agreements which by their terms contemplate performance after the Closing shall survive until the date specified
in this Agreement or the Transaction Documents as the termination date for such covenants and agreements, or if no such date is
specified, then such covenants and agreements shall survive until the expiration of any statute of limitations.

 

Section
7.2 Seller’s Agreement to Indemnify. Subject to the terms, conditions and limitations of this Agreement, the Seller
agrees to indemnify, defend and hold harmless Buyer, its officers, employees, directors and agents (collectively, the “Buyer
Indemnitees”) from and against all Damages (as defined below) to which Buyer becomes subject as a result of, arising
out of, or based on any of the following:

 

	 	(a)	a
    breach of any representation or warranty made by the Seller pursuant to this Agreement in Article IV;

 

    	12

    	 

    

 

	 	(b)	a
    breach of any covenant contained in or made by the Seller pursuant to this Agreement;
	 	 	 
	 	(c)	any
    liabilities or obligations arising directly or indirectly with respect to the Assets, including without limitation any Encumbrances
    on the Assets and any Taxes owed directly or indirectly with respect to the Assets for any period prior to the Closing Date;
    and
	 	 	 
	 	(d)	any
    claim or liability for brokerage commissions or finder’s fees incurred by reason of any action taken by Seller or any
    of its affiliates.

 

“Damages”
shall mean all demands, claims, actions or causes of action, assessments, judgments, fines, losses, damages, liabilities, costs
and expenses, including, without limitation, interest, penalties, punitive and exemplary damages, costs of investigation, clean-up
and remediation and attorneys’ fees and reasonable expenses.

 

Section
7.3 Buyer’s Agreement to Indemnify. Subject to the terms, conditions and limitations of this Agreement, Buyer agree
to indemnify, defend and hold harmless Seller, its officers, employees, managers, and agents (collectively, the “Seller
Indemnitees”), from and against all Damages to which Seller becomes subject as a result of, arising out of, or based
in any of the following:

 

	 	(a)	a
    breach of any representation or warranty made by Buyer pursuant to this Agreement in Article III;
	 	 	 
	 	(b)	a
    breach of any covenant contained in or made by Buyer pursuant to this Agreement; and
	 	 	 
	 	(c)	any
    claim or liability for brokerage commissions or finder’s fees incurred by reason of any action taken by Buyer.  

 

Section
7.4 Procedures for Resolution and Payment of Claims for Indemnification.

 

	 	(a)	If
    a party entitled to be indemnified under this Article (the “Indemnitee”) shall incur any Damages or determines
    that it is likely to incur any Damages, and believes that it is entitled to be indemnified against such Damages by the other
    party hereunder (the “Indemnitor”), such Indemnitee shall give prompt notice to the Indemnitor of the assertion
    of any claim, or the commencement of any action, suit or proceeding, in respect of which indemnity may be sought hereunder
    and will give the Indemnitor such information with respect thereto as the Indemnitor may reasonably request (“Indemnitee’s
    Certificate”), but failure to give such notice shall relieve the Indemnitor of any liability hereunder only to the
    extent that the Indemnitor has suffered actual prejudice thereby.

 

    	13

    	 

    

 

	 	(b)	In
    case the Indemnitor shall object to the indemnification of an Indemnitee in respect of any claim or claims specified in any
    Indemnitee’s Certificate, the Indemnitor shall within thirty (30) days after receipt by the Indemnitor of such Indemnitee’s
    Certificate deliver to the Indemnitee a written notice to such effect and the Indemnitor and the Indemnitee shall, within
    the thirty (30) day period beginning on the date of receipt by the Indemnitee of such written objection, attempt in good faith
    to agree upon the rights of the respective parties with respect to each of such claims to which the Indemnitor shall have
    so objected.  If the Indemnitee and the Indemnitor shall succeed in reaching agreement on their respective rights
    with respect to any of such claims, the Indemnitee and the Indemnitor shall promptly prepare and sign a memorandum setting
    forth such agreement.  In the event the Indemnitee and the Indemnitor do not succeed in reaching agreement on their
    respective rights with respect to any such claims (“Disputed Claims”), the Disputed Claims will be resolved
    in accordance with Section 10.8(b) herein.
	 	 	 
	 	(c)	Claims
    for Damages specified in any Indemnitee’s Certificate to which an Indemnitor shall not object in writing and claims
    for Damages resolved in accordance with Section 7.4(b) and Section 10.8(b) are hereinafter referred to, collectively, as “Agreed
    Claims.” 
	 	 	 
	 	(d)	Promptly
    after the assertion by any third party of any claim against any Indemnitee that, in the reasonable judgment of such Indemnitee,
    will result in the incurrence by such Indemnitee of Damages for which such Indemnitee would be entitled to indemnification
    pursuant to this Agreement, such Indemnitee shall deliver to the Indemnitor a written notice describing in reasonable detail
    such claim and such Indemnitor may, at its option, assume the defense of the Indemnitee against such claim (including the
    employment of counsel, who shall be reasonably satisfactory to such Indemnitee, and the payment of expenses).  Failure
    to receive notice from Indemnitee shall not amend any rights, obligations or limitations set forth in this Article.  Any
    Indemnitee shall have the right to employ separate counsel in any such action or claim and to participate in the defense thereof,
    but the Indemnitor shall not be responsible for the fees and expenses of such counsel unless (i) the Indemnitor shall have
    failed, within a reasonable time after having been notified by the Indemnitee of the existence of such claim as provided in
    the preceding sentence, to assume the defense of such claim, (ii) the employment of such counsel has been specifically authorized
    by the Indemnitor, or (iii) the named parties to any such action (including any impleaded parties) include both such Indemnitee
    and Indemnitor and such Indemnitee shall have furnished Indemnitor an opinion of counsel to the effect that there may be one
    or more legal defenses available to Indemnitee which are different from or additional to those available to Indemnitor, in
    which event Indemnitor shall only be responsible for the fees and expenses of one separate firm of attorneys for all Indemnitees.  If
    the Indemnitor, within a reasonable time after notice of any such third party claim, fails in good faith to defend the Indemnitee
    against such claim, the Indemnitee shall have the right to undertake the defense, compromise or settlement of such claim on
    behalf of and for the account and risk of the Indemnitor, subject always to the right of the Indemnitor to assume the defense
    of such claim at any time prior to settlement, compromise or final determination thereof.  No Indemnitor shall be
    liable to indemnify any Indemnitee for any settlement or compromise of any such action or claim effected without the consent
    of the Indemnitor which shall not be unreasonably withheld or delayed; but if settled with the written consent of the Indemnitor,
    or if there be a final judgment for the plaintiff or claimant in any such action, the Indemnitor shall indemnify and hold
    harmless each Indemnitee from and against any loss or liability by reason of such settlement or judgment (but only to the
    extent provided in this Article).

 

    	14

    	 

    

 

Section
7.5 Payment of Agreed Claims. Upon the occurrence of any event or existence of any condition which result in a claim for
indemnification under this Article, such party shall initiate a claim under Section 7.4 of this Agreement.

 

ARTICLE
VIII

COVENANTS
OF THE SELLER

 

Section
8.1 Covenants. The Seller agrees that from the date of this Agreement until the Closing Date, the Seller will not take
any action which would render any of the representations or warranties contained in this Agreement to be false or inaccurate.

 

Section
8.2 Cooperation Post Closing. If requested by Buyer, Seller will cooperate upon and after the Closing Date in effecting
the orderly transfer of the Assets to Buyer. Without limiting the generality of the foregoing, Seller, at the request of Buyer
and without additional consideration, will execute and deliver from time to time such further instruments of assignment, conveyance
and transfer, will sign any documents necessary or useful to ensure that all of the right, title and interest in and to the Assets
vests in Buyer, and will take such other actions as may reasonably be required to convey and deliver to Buyer more effective title
to the Assets, or to confirm and perfect Buyer's title thereto, as contemplated by this Agreement.

 

    	15

    	 

    

 

ARTICLE
IX

TERMINATION

 

Section
9.1 Termination of Agreement. This Agreement may be terminated:

 

	 	(a)	prior
    to the Closing by mutual agreement of the parties; or
	 	 	 
	 	(b)	prior
    to the Closing by Buyer if any of the conditions provided for in Article V of this Agreement have not been met at the Closing
    and have not been waived in writing by Buyer prior to such date; or
	 	 	 
	 	(c)	prior
    to the Closing by Seller if any of the conditions provided for in Article VI of this Agreement have not been met at the Closing
    and have not been waived in writing by Seller prior to such date.

 

Section
9.2 Termination Procedure; Effect of Termination.

 

	 	(a)	In
    the event of termination by Seller or Buyer, or by the mutual agreement of Seller and Buyer, pursuant to Section 9.1 of this
    Agreement, written notice thereof shall forthwith be given to the other party and the transactions contemplated by this Agreement
    shall be terminated, without further action or liability by either party or parties to the other (except for liability of
    any party for the willful breach of this Agreement).  
	 	 	 
	 	(b)	If
    the transactions contemplated by this Agreement are terminated as provided herein, Seller and Buyer shall return all documents,
    work papers and other material of any other party relating to the transactions contemplated hereby, whether so obtained before
    or after the execution of this Agreement, to the party furnishing the same; and such termination shall not in any way limit
    or restrict the rights and remedies of any party hereto against any other party which has breached any of the agreements or
    other provisions of this Agreement prior to termination of this Agreement. 
	 	 	 
	 	(c)	In
    the event this Agreement is terminated, each party will keep confidential any information (unless such information is public
    information or is otherwise required by law to be disclosed) obtained from the other party in connection with the transactions
    contemplated hereby and will not use, develop or disclose any such information in any manner whatsoever based on information
    provided by the other for a period of two (2) years.

 

ARTICLE
X

MISCELLANEOUS

 

Section
10.1 Further Assurances. Each party hereto shall execute and cause to be delivered to each other party hereto such instruments
and other documents, and shall take such other actions, as such other party may reasonably request (prior to, at, or after the
Closing) for the purpose of carrying out or evidencing any of the transactions contemplated by this Agreement.

 

    	16

    	 

    

 

Section
10.2 Fees and Expenses. All fees, costs and expenses (including legal fees and accounting fees) that have been incurred
or that are incurred in the future by any party in connection with the transactions contemplated by this Agreement, including
all fees, costs and expenses incurred by such party in connection with or by virtue of (a) any investigation and review conducted
by such party of the other party's business (and the furnishing of information in connection with such investigation and review),
(b) the negotiation, preparation and review of this Agreement and all agreements, certificates, opinions and other instruments
and documents delivered or to be delivered in connection with the transactions contemplated by this Agreement, (c) the preparation
and submission of any filing or notice required to be made or given in connection with any of the transactions contemplated by
this Agreement, and the obtaining of any Consent required to be obtained in connection with any of such transactions, and (d)
the consummation of the transactions contemplated hereby shall be paid: (i) by Buyer, if incurred by Buyer; and (ii) by Seller,
if incurred by Seller.

 

Section
10.3 Attorneys' Fees. If any action or proceeding relating to this Agreement or the enforcement of any provision of this
Agreement is brought against any party hereto, the prevailing party shall be entitled to recover reasonable attorneys' fees, costs
and disbursements (in addition to any other relief to which the prevailing party may be entitled).

 

Section
10.4 Notices. Any notice or other communication required or permitted to be delivered to any party under this Agreement
shall be in writing and shall be deemed properly delivered, given and received when delivered (by hand, by registered mail, by
courier or express delivery service or by facsimile) to the address or facsimile telephone number set forth beneath the name of
such party below (or to such other address or facsimile telephone number as such party shall have specified in a written notice
given to the other party hereto):

 

	 	if
    to Buyer:	PureBase
    Corporation
	 	 	8625
    State Hwy. 124
	 	 	Ione,
    CA 95640
	 	 	Attn:
    A. Scott Dockter, Chief Executive Officer

 

With
a copy to (which shall not constitute notice):

 

	 	The
    Crone Law Group P.C.
	 	500
    Fifth Avenue
	 	Suite
    938
	 	New
    York, NY 10110
	 	Attn:
    Eric Mendelson, Esq.

 

	 	if
    to Seller:	Quove
    Corporation
	 	 	3860
    So. Jason Street
	 	 	Englewood,
    Co. 80110
	 	 	Attn:
    Mark A. Bogani, President

 

    	17

    	 

    

 

With
a copy to (which shall not constitute notice):

 

	 	Hart
    & Hart, LLC
	 	1624
    Washington Street
	 	Denver,
    CO. 80203
	 	Attn:
    Bill Hart

 

Section
10.5 Severability. In the event that any provision of this Agreement, or the application of any such provision to any Person
or set of circumstances, shall be determined to be invalid, unlawful, void or unenforceable to any extent, the remainder of this
Agreement, and the application of such provision to Persons or circumstances other than those as to which it is determined to
be invalid, unlawful, void or unenforceable, shall not be impaired or otherwise affected and shall continue to be valid and enforceable
to the fullest extent permitted by law.

 

Section
10.6 Headings. The Section headings contained in this Agreement are for convenience of reference only, shall not be deemed
to be a part of this Agreement and shall not be referred to in connection with the construction or interpretation of this Agreement.

 

Section
10.7 Counterparts. This Agreement may be executed in two or more identical counterparts, each of which shall be deemed
an original but all of which together will constitute one and the same instrument. This Agreement, any and all agreements and
instruments executed and delivered in accordance herewith, along with any amendments hereto and thereto, to the extent signed
and delivered by means of email or other electronic transmission, shall be treated in all manner and respects and for all purposes
as an original signature, agreement or instrument and shall be considered to have the same binding legal effect as if it were
the original signed version thereof delivered in person.

 

Section
10.8 Governing Law; Arbitration.

 

(a)
This Agreement shall be construed in accordance with, and governed in all respects by, the internal laws of the State of Nevada
(without giving effect to principles of conflicts of laws).

 

(b)
Buyer, on the one hand, and Seller, on the other, shall promptly submit any dispute, claim or controversy arising out of or relating
to this Agreement and the other Transaction Documents (including, without limitation, with respect to the meaning, effect, validity,
termination, interpretation, performance or enforcement of this Agreement or such Transaction Document) or any alleged breach
(including any action in tort, contract, equity or otherwise) to binding arbitration before one arbitrator. The parties agree
that, except as otherwise provided herein respecting temporary or preliminary injunctive relief, binding arbitration shall be
the sole means of resolving any dispute, claim or controversy arising out of or relating to this Agreement or any Transaction
Document (including, without limitation, with respect to the meaning, effect, validity, termination, interpretation, performance
or enforcement of this Agreement or such Transaction Document) or any alleged breach (including any claim in tort, contract, equity
or otherwise). Such arbitration shall be conducted by the American Arbitration Association under the Arbitration Rules then in
effect, and shall take place in Las Vegas, Nevada.

 

    	18

    	 

    

 

Section
10.9 Successors and Assigns. This Agreement shall be binding upon and inure to the benefit of the parties hereto and their
respective successors and assigns. This Agreement may not be assigned by either party, other than the Buyer which can assign this
Agreement and all its rights hereunder to a wholly owned subsidiary.

 

Section
10.10 Remedies Cumulative; Specific Performance. The rights and remedies of the parties hereto shall be cumulative (and
not alternative). The parties to this Agreement agree that, in the event of any breach or threatened breach by any party to this
Agreement of any covenant, obligation or other provision set forth in this Agreement for the benefit of any other party to this
Agreement, such other party shall be entitled (in addition to any other remedy that may be available to it) to (a) a decree or
order of specific performance or mandamus to enforce the observance and performance of such covenant, obligation or other provision,
and (b) an injunction restraining such breach or threatened breach.

 

Section
10.11 Waiver. No failure on the part of any party to exercise any power, right, privilege or remedy under this Agreement,
and no delay on the part of any party in exercising any power, right, privilege or remedy under this Agreement, shall operate
as a waiver of such power, right, privilege or remedy; and no single or partial exercise of any such power, right, privilege or
remedy shall preclude any other or further exercise thereof or of any other power, right, privilege or remedy. No party shall
be deemed to have waived any claim arising out of this Agreement, or any power, right, privilege or remedy under this Agreement,
unless the waiver of such claim, power, right, privilege or remedy is expressly set forth in a written instrument duly executed
and delivered on behalf of such party; and any such waiver shall not be applicable or have any effect except in the specific instance
in which it is given.

 

Section
10.12 Amendments. This Agreement may not be amended, modified, altered or supplemented other than by means of a written
instrument duly executed and delivered on behalf of all of the parties hereto.

 

Section
10.13 Entire Agreement. This Agreement and the attached Exhibits and Schedules set forth the entire understanding of the
parties hereto relating to the subject matter hereof and thereof and supersedes all prior agreements and understandings among
or between any of the parties relating to the subject matter hereof.

 

[Remainder
of Page Intentionally Left Blank; Signatures to Follow]

 

    	19

    	 

    

 

The
parties hereto have caused this Asset Purchase Agreement to be executed and delivered as of the date first above written.

 

	 	SELLER:
	 	 
	 	QUOVE CORPORATION 
	 	 
	 	By:	/s/
    Mark A. Bogani
	 	Name:	Mark
    A. Bogani
	 	Title:	President
	 	 	 
	 	BUYER:
	 	 
	 	PUREBASE CORPORATION 

 

	 	By:
    	/s/
    A. Scott Dockter
	 	Name:
    	A.
    Scott Dockter
	 	Title:   	Chief
    Executive Officer

 

    	 

    	 

    

 

EXHIBIT
A

BILL
OF SALE AND ASSIGNMENT

 

KNOW
ALL MEN BY THESE PRESENTS THAT, for good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged,
the undersigned, QUOVE CORPORATION, a Colorado corporation ("Seller"), does hereby sell, assign, convey, transfer
and delivery to PUREBASE CORPORATION, a Nevada corporation ("Buyer"), all of Seller's rights, title and interest
in and to the Assets. Capitalized terms used herein not otherwise defined shall have the meanings ascribed to such terms in the
Asset Purchase Agreement dated April __, 2020 (the “Asset Purchase Agreement”) by and between Seller and Buyer.

 

Seller
hereby warrants to Buyer, its successors and assigns, that Seller is the rightful owner of the Assets conveyed; that Seller is
conveying to Buyer good and merchantable title to the Assets conveyed, free and clear of all liabilities, obligations, claims,
and Encumbrances of any kind or nature; and that Seller (and Seller's successors and assigns) will warrant and defend this sale
against the claims and demands of all persons whomsoever.

 

Seller
hereby covenants and agrees that it will, at the request of Buyer and without further consideration, execute and deliver, and
will cause its employees to execute and deliver, such other instruments of sale, transfer, conveyance and assignment, and take
such other action as may be reasonably necessary to vest in Buyer, its successors and assigns, good and merchantable title to
the Assets conveyed, free and clear of all liabilities, obligations, claims, and encumbrances of any kind or nature and to put
Buyer in control and possession thereof.

 

Seller
does hereby irrevocably constitute Buyer, its successors and assigns, as Seller's true and lawful attorney-in-fact, with full
power of substitution, in Seller's or Buyer's name, to claim, demand, collect and receive the Assets conveyed.

 

This
instrument is being delivered in connection with the Asset Purchase Agreement and is subject to, and is entitled to the benefits
in respect of, said agreement.

 

This
instrument shall be binding upon Seller and its successors and assigns and shall inure to the benefit of Buyer and its successors
and assigns.

 

Dated
this ___ day of _______, 2020.

 

	QUOVE
    CORPORATION 	 
	 	 	 
	By:	 	 
	Name:	Mark
    A. Bogani	 
	Title:  	PresidentDocument

Exhibit 10.1

Cigna Corporation

Cigna Long-Term Incentive Plan:  Strategic Performance Share Grant Agreement

Cigna Corporation (“Cigna”) has granted you the number of strategic performance shares set forth below in this Strategic Performance Share Grant Agreement (“Strategic Performance Share Grant” or “Grant”) under the Cigna Long-Term Incentive Plan (“Plan”).  The date of your Strategic Performance Share Grant (“Grant Date”) is also indicated below. The award is subject to the provisions of the Plan and the Terms and Conditions below.
  
The award of Shares pursuant to this Strategic Performance Share Grant is expressly conditioned on your acceptance of the terms and conditions of this Grant and of the attached Confidentiality, Non-Competition and Non-Solicitation Agreement (or with respect to Cigna company employment in California, the attached Confidentiality and Non-Solicitation Agreement) (as applicable, the “Covenant Agreement”).  You should carefully read all the terms and conditions of this Strategic Performance Share Grant and the attached Covenant Agreement and be sure you understand what they say and what your responsibilities and obligations are before you click on the ACCEPT button to acknowledge and agree to this Grant.  

If you are not willing to agree to all of the Grant and Covenant Agreement terms and conditions, do not accept the Grant and do not click the ACCEPT button for the Strategic Performance Share Grant Acknowledgment and Agreement.  If you do not accept the Grant, you will not receive the benefits of the Grant. 
 
If you do click on the ACCEPT button, you are accepting and agreeing to all of the terms and conditions of this Strategic Performance Share Grant and the Covenant Agreement, which include, among other things, restrictive covenants such as non-competition, customer and employee non-solicitation and non-disclosure provisions and  litigation cooperation and intellectual property assignment and assistance provisions.

Participant:  
Grant Type:   
Plan Name:  Cigna Long-Term Incentive Plan

Grant Date:  
Total Granted:  
Grant Price:  (USD)

Vesting Schedule
						
	Shares Granted	Approximate Vest Date
		

Please Note: The date shown in the Vesting Schedule chart above is not your actual vesting date.  It is an approximation of the expected vesting date and is provided due to systems requirements. In accordance with the Terms and Conditions of your Strategic Performance Share Grant, the actual vesting date will be determined by the People Resources Committee of the Board of Directors.

In addition to this Strategic Performance Share Grant and the attached Covenant Agreement, you should also read the Plan Document and Key Contacts and Reference Materials document (attached 

to the Plan) and indicate that you have done so and agree to the terms of all documents attached to this Grant by checking the appropriate box in the online grant acceptance process.  The Key Contacts and Reference Materials document contains information on how to get important award information (such as the Plan Prospectus, Tax Considerations and Cigna's Securities Transactions and Insider Trading Policy) and whom to contact if you have questions.

Please be aware that the Cigna Securities Transactions and Insider Trading Policy places restrictions on your transactions in Cigna securities and requires certain Cigna employees to obtain advance permission from the Corporate Secretary before executing transactions in Cigna securities.

If you have questions about your award, please contact Cigna Shareholder Services by email at shareholderservices@cigna.com or by phone at 215.761.3516.

2

Important Notice:  Strategic Performance Share Grant and Covenant Agreement Acknowledgment and Agreement

By clicking on the ACCEPT button, I:

Acknowledge and represent to Cigna that I have: 
1. received the Strategic Performance Share Grant and the Covenant Agreement;
2. read and understand their terms and conditions, which include, among other things, restrictive covenants such as non-competition, customer and employee non-solicitation and non-disclosure provisions and litigation cooperation and intellectual property assignment and assistance provisions; and 
3. received answers to any questions I had about the Grant and the Covenant Agreement and their terms and conditions, including the applicable restrictive covenants. 

Scroll down for the TERMS AND CONDITIONS of the Strategic Performance Share Grant.
        TERMS AND CONDITIONS OF YOUR [Year] GRANT
3

        OF STRATEGIC PERFORMANCE SHARES

These Terms and Conditions are an important part of your grant of Strategic Performance Shares from Cigna Corporation (Cigna).  The terms of your Strategic Performance Share grant are in: (a) the electronic Strategic Performance Share Grant Agreement above, (b) these Terms and Conditions (including Schedule I), (c) the Covenant Agreement, and (d) the Cigna Long-Term Incentive Plan (Plan).  
Certain words in this document with first letters capitalized are defined in the Strategic Performance Share Grant Agreement above, these Terms and Conditions or Article 2 of the Plan.  This grant is void if you are not an employee of Cigna or a Subsidiary (a Cigna company) on the Grant Date.

1. Strategic Performance Shares; Performance Period
Each Strategic Performance Share (Performance Share) represents a conditional right to receive one share of Cigna Common Stock (Share), subject to the performance, vesting and payment provisions described below. The Performance Period applicable to your award is January 1, [ ] to December 31, [ ] (the Performance Period). 
2.  Restrictions
Performance Shares are subject to certain Restrictions from the Grant Date until the Payment Date described in paragraph 4.  The Restrictions are: 
(a)  You cannot sell or transfer the Performance Shares to anyone; 
(b)  Unless an exception applies (described in paragraph 4), you will forfeit (lose your right to) your unvested Performance Shares and all related rights immediately upon your Termination of Employment; and
(c) Of the Performance Shares awarded to you (Shares Awarded), the number of Performance Shares, if any, that you earn and for which you may receive payment (Shares Earned) is subject to the performance criteria described in Schedule I.  
Article 10 of the Plan describes these Restrictions in more detail.  In addition to these Restrictions, you must also comply with all the terms and conditions of this grant and the Covenant Agreement. 

3. Performance Shares Earned 
(a) Schedule I specifies the performance criteria applicable to your Shares Awarded. Except as provided in paragraph 4, after the end of the Performance Period, the Committee shall determine whether and to what extent these performance criteria have been achieved for purposes of determining the Vesting Percentage applicable to your Performance Shares (Shares Earned Percentage). 
(b) Any Shares Awarded that are not Shares Earned after giving effect to the Committee’s determinations under this paragraph 3 shall terminate and become null and void immediately following such determinations.
4.  Eligibility for Payment
(a) Except as described in paragraph 4(b) and subject to paragraph 4(c) and paragraph 3, the Restrictions on the Performance Shares will end (your Performance Shares will vest) on the Payment Date described in paragraph 5, but only if you remain continuously employed by a Cigna company until the Payment Date and comply with all the terms and conditions of this grant and the Covenant Agreement. 
4

(b) Notwithstanding paragraph 4(a) and subject to paragraph 4(c) and paragraph 3, if your Termination of Employment is before the Payment Date: 
        (1) Your Performance Shares will vest upon your Termination of Employment if it is Upon a Change of Control. If your Performance Shares vest under this paragraph 4(b)(1), the Shares Earned Percentage shall be the greatest of:
         (a) 100%;
         (b) The Shares Earned Percentage for the Performance period that ended immediately before your Termination upon a Change of Control; or
         (c) The average of the Shares Earned Percentages established by the Committee for the last two Performance Periods that ended before your Termination upon a Change of Control.
Whether there is a Termination Upon a Change of Control for purposes of this Strategic Performance Share grant is determined by reference to a Change of Control (as defined in the Plan) of the entity issuing this grant (Cigna Corporation) and not by reference to a Change of Control of any predecessor entity of Cigna Corporation.  
  (2) Your Performance Shares will vest upon your Termination of Employment if it is due to your death. If your Performance Shares vest under this paragraph 4(b)(2), the Shares Earned Percentage shall be 100%. 
        (3) Your Performance Shares will vest upon your Termination of Employment if it is due to your Disability.  
        (4) Your Performance Shares may vest upon your Termination of Employment if it is due to your Early Retirement or Retirement and if the Committee or its designee (including Cigna’s Senior Human Resources Officer) approves the early vesting before your Termination of Employment.  If you want to be considered for early vesting when you retire, you must ask your manager or human resources representative far enough in advance of your retirement so there is time to process your request.
(c) You must comply in all respects with the terms and conditions of this Grant and the Covenant Agreement.   

5. Payment
(a) Except as provided in paragraph 5(b), below, your vested Shares Earned under this grant will be paid in the year following the close of the Performance Period on the date within such year specified by the Committee (Payment Date). 
(b) Any Performance Shares that vest on account of your death will be paid during the 90 day period immediately following your death to your estate.  
(c) For each Share Earned that vests, Cigna will make payment by issuing one Share as of the Payment Date.  Until the Shares are issued to you, you will not be a Cigna shareholder, not have the right to vote the Shares, and not receive actual dividends.

6. Taxes 
Section 16.7 of the Plan shall apply to any tax withholding that may be required by law for Performance Shares or Shares.  Upon the vesting or payment of any Performance Share, Cigna 
5

reserves the right to withhold enough newly-issued Shares to cover all or part of any applicable tax withholding.

7. Book-Entry Shares; Sale of Shares
(a) Upon payment of the Shares as described in paragraph 5, Cigna (or a custodian appointed by Cigna) will hold your Shares in book-entry form in a Stock Account.  That is, a record of your Share ownership will be kept electronically.  
(b) You may generally sell or transfer the Shares at any time, but your right to sell the Shares may be limited by Cigna.  This right is subject to the terms of Cigna's Securities Transactions and Insider Trading Policy, and Cigna reserves the right, for any reason at any time, to suspend or delay action on any request you make to sell the Shares.

8. Conditions of Grant
(a) By accepting the grant, you are agreeing:
        (1)  to the Inventions provision in paragraph 8(b);
        (2) to the restrictions contained in the attached Covenant Agreement and in paragraph 8(c)(2) below (such restrictions collectively, the “Promises”);
        (3) to notify Cigna if you accept an offer to perform services for any individual or entity while you are subject to the non-competition Promise under the Covenant Agreement.  Such notice shall be provided by email to Cigna Shareholder Services (shareholderservices@Cigna.com) within 10 days of your acceptance of the offer and shall identify the individual or entity and your anticipated start date; 
        (4) to disclose the terms of the Promises (including, without limitation, the Promises related to non-solicitation and non-competition) and the consequences of a Violation (as defined below) to any individual or entity for whom you perform services during the 12 month period immediately following your Termination of Employment; and 
        (5) not to engage in any activity that would constitute a Violation (as defined below).  
        You understand and agree that the conditions of the grant set forth in this paragraph 8(a) are a material part of the inducement for Cigna's granting you the Performance Shares and essential pre-conditions to your eligibility to exercise any rights associated with the Grant and retain any benefit from the vesting of the Performance Shares and issuance of the Shares. 
        The award of Shares pursuant to this Strategic Performance Share Grant is expressly conditioned on your acceptance of the terms and conditions of this Grant and of the attached Covenant Agreement.  If you decide to accept this Strategic Performance Share Grant, you are accepting and agreeing to all of the terms and conditions of this Grant and of the attached Covenant Agreement, which include, among other things, restrictive covenants such as non-competition, customer and employee non-solicitation and non-disclosure provisions and litigation cooperation and intellectual property assignment and assistance provisions.
        You should review the terms of this Grant and the Covenant Agreement carefully to ensure that you understand what they say and what your responsibilities and obligations are before you click on the accept button to acknowledge and agree to this Grant. 
6

(b)  Inventions 
        (1) You hereby assign and promise to assign to Cigna companies or their designee, all your right, title, and interest in and to any and all current and future Inventions.  You acknowledge that all original works of authorship which you make (whether alone or jointly with others) within the scope of your Cigna company employment and which are protectable by copyright are “works made for hire,” as defined in the United States Copyright Act.
        (2) You agree to (i) maintain and make available adequate current records, including electronic records, notes, sketches and drawings, of all Inventions you make, and (ii) disclose such Inventions in writing upon request. These records will remain the property of Cigna companies.
        (3) If in the course of your Cigna company employment, you incorporate a Prior Invention into any Cigna company work product, you grant Cigna companies a nonexclusive, royalty-free, irrevocable, perpetual, worldwide license to use the Prior Invention as part of or in connection with the work product. Within 45 days after the date of this grant, you agree to notify Cigna Shareholder Services (shareholderservices@Cigna.com) of any Prior Inventions that you are not assigning under this paragraph 8(b).
        (4) “Inventions” means any and all inventions, original works of authorship, developments, concepts, sales methods, improvements, trade secrets, or similar intellectual property, whether or not patentable or registrable under copyright or similar laws, that relate to any Cigna company’s current or proposed business, work products or research and development which you have or will solely or jointly conceive, develop, reduce to practice, or fix during your Cigna company employment.
        (5) “Prior Inventions” means all inventions, original works of authorship, developments, concepts, sales methods, improvements, trade secrets or similar intellectual property, whether or not patentable or registrable under copyright or similar laws, that relate to any Cigna company’s current or proposed business, work products or research and development which you conceived, developed, reduced to practice or fixed before your Cigna company employment and which belong to you.   
(c) Violation
        You will engage in a “Violation” if, directly or indirectly, you engage in any willful misconduct as described in paragraph 8(c)(1) below or you break any of the “Promises”.
(1) Willful Misconduct: 
(A) You have a Termination of Employment initiated by a Cigna company because you engaged in conduct that constitutes a gross violation of Cigna's Code of Ethics and Principles of Conduct or other employment policies.
(B) You do anything else while an employee of any Cigna company that is not discovered by the company until after your Termination of Employment and that would, if you had still been employed at the time of the discovery, be reason for your Termination of Employment for willful misconduct, as described above.
(2) Promise to Assist with Patent and Copyright Registrations:  
7

(A) You Promise that, during your Cigna company employment and after your Termination of Employment, you will assist Cigna companies, should they request and at Cigna's expense, to secure their rights (including any copyrights, patents, trademarks or other intellectual property rights) in or relating to the Inventions in any and all countries, including by: 
(i)disclosing to Cigna Companies all pertinent information and data; and
(ii)executing all applications, assignments or other instruments necessary to apply for and obtain these rights and assign them to Cigna companies.   
(d) (1) If you were an Executive Officer (subject to the requirements of Section 16(a) of the Exchange Act) at any time during the 24-month period before the date of a Violation of the Covenant Agreement, the People Resources Committee will have the sole discretion to waive your obligation to make all or any part of the Payment (described in paragraph 9) and to impose conditions on any waiver.  
(2) Otherwise, Cigna's Senior Human Resources Officer, or his or her designee, will have the sole discretion to waive your obligation to make all or any part of the Payment and to impose conditions on any waiver.  
(3) Determinations of the People Resources Committee, Cigna's Senior Human Resources Officer, or his or her designee, will be final and binding on all parties.

9. Consequences of a Violation: Payment to Cigna 
Important: This paragraph 9 is not Cigna's only remedy for a Violation.  Cigna may seek any additional legal or equitable remedy, including as described in the Covenant Agreement.
(a) If you engage in any Violation at any time:
        (1) You will immediately forfeit all unvested Performance Shares; and
        (2) No payment will be made for any Performance Shares that have vested under paragraph 4(b) if the Violation occurs before the applicable Payment Date.
 (b) You must immediately make the Payment described in paragraph 9(c) to Cigna in the manner described in paragraph 9(d) if:
(1) You engage in a Violation of the non-competition or non-solicitation restrictions of the Covenant Agreement; or
(2) You engage in a Violation described in paragraph 8(c)(1) (willful misconduct) or any other Violation (e.g. you disclose Cigna company Confidential Information in violation of the Covenant Agreement) at any time. 
(c) “Payment” is the value you realize from any Performance Shares that are paid under paragraph 5 during the 12-month period ending on (and including) the date of your Termination of Employment.  The Payment will equal:
(1) The number of Performance Shares that are paid during that 12-month period; 
         multiplied by 
(2) The Fair Market Value of the Shares issued on the Payment Date for those Performance Shares; 
         plus 
8

(3) The total amount of all actual dividends, if any, paid to you on those Shares through the date of the Payment described in paragraph 9(d).  
(d) Cigna will recover the Payment from you by any means permitted by applicable law, at the sole discretion of Cigna management, including but not limited to any or all of the following methods: 
(1) If you have any Shares in a Stock Account or in any other account in book-entry form when a Violation occurs, Cigna will take back from you the whole number of Shares that has a total Fair Market Value as of the date of the Violation up to, but not more than, the Payment amount.
(2) Cigna will, to the extent permitted by applicable law, reduce:
(A) The amount of any payments that any Cigna company owes you for any reason (including without limit any payments owed to you under any nonqualified retirement, deferred compensation or other plan or arrangement) by 
(B) The Payment amount.  
        This reduction will not occur until the date a future payment to you is due.
(3) Cigna will send you a written notice and demand for all or part of any Payment amount.  Within 30 days after you receive that notice and demand, you must make the Payment to Cigna.

10. Consequences of a Violation: Designation of Cigna as Agent and Attorney-in-Fact for Inventions
You agree that:
(a) If Cigna Companies are unable to obtain your signature on any instruments needed to secure their rights in or relating to the Inventions pursuant to paragraph 8(c)(2)(A); then
(b) You hereby appoint Cigna companies and their duly authorized officers as your agents and attorneys in fact to act for and on your behalf to execute and file any documents and take other actions as may be necessary for Cigna companies to secure those rights.
11. Agreeing to Assume Risks
Cigna, its stock plan administrator and its transfer agent will try to process your stock transaction requests in a timely manner; however, Cigna makes no promises or guarantees to you relating to the market price of the Shares or to the time it may take to act on your request to sell the Shares.  By accepting this Strategic Performance Share grant:
(a) You acknowledge that the action you request may not be completed until several days after you submit it.    
(b) You agree to assume the risks, including the risk that the market price of the Shares may change, related to delays described in paragraph 11(a) between the time you ask for any Shares to be sold and the time your Shares are actually sold.
12. Applicable Law
You understand and agree that, except as otherwise provided in the Covenant Agreement, the terms and conditions of this Strategic Performance Share Grant and all determinations made under the Strategic Performance Share Grant Agreement, the Plan, and these Terms and Conditions will be interpreted under the laws of the State of Delaware, without regard to its conflict of laws rule. 
9

For the avoidance of doubt, the terms and conditions of the Covenant Agreement and all determinations made under the Covenant Agreement will be interpreted under applicable state law as set forth in the Covenant Agreement. 
13. Arbitration 
Except as otherwise provided in the Covenant Agreement, if you have an agreement with Cigna to arbitrate employment-related disputes, you agree to resolve any disputes relating to this Strategic Performance Share Grant through arbitration. 
14. Acceptance
If you disagree with any of these Terms and Conditions, or the terms and conditions of the Covenant Agreement, YOU MUST NOT ACCEPT THE STRATEGIC PERFORMANCE SHARE GRANT.  If you sign the Strategic Performance Share grant, or the Covenant Agreement, or acknowledge your acceptance electronically or otherwise, you will be: 
(a)  Agreeing to all the terms and conditions of the Strategic Performance Share grant and of the Covenant Agreement, including the Inventions provision in paragraph 8(b) and all of the Promises; 
(b)  Warranting and representing to Cigna that you are, and will remain, in full compliance with all applicable terms and conditions; 
(c)  Authorizing Cigna to recover the Payment described in paragraph 9 and to seek any other available remedy pursuant to the Covenant Agreement, if you engage in a Violation; and

(d) Appointing Cigna as your agent and attorney-in-fact to secure rights with respect to Inventions if unable to obtain your signature as described in paragraph 10.
  
[Year] US SPS Grant Agreement including Terms and Conditions
10

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00308-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00308-of-00352.parquet"}]]